STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] MARIMED INC. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

MariMed (MRMD) President & CEO Jon R. Levine reported equity award activity. On November 7, 2025, 75,000 RSUs converted into common stock (Code M) at $0, and 22,013 shares were withheld to satisfy taxes (Code F) at $0.097.

Following these transactions, he holds 21,006,481 shares directly and 6,684,640 shares indirectly by the Jon Levine Family Trust. 150,000 RSUs remain outstanding, scheduled to vest in equal installments on May 7, 2026 and November 7, 2026.

Positive
  • None.
Negative
  • None.

Insights

Routine RSU vesting with tax withholding; neutral impact.

MariMed CEO Jon R. Levine reported a standard RSU vesting event. 75,000 RSUs converted to common stock on November 7, 2025 (Code M) at $0, reflecting the one-for-one RSU-to-share conversion.

To cover taxes, 22,013 shares were withheld at $0.097 (Code F). Post-transaction holdings are 21,006,481 shares directly and 6,684,640 indirectly via a family trust. 150,000 RSUs remain and are set to vest equally on May 7, 2026 and November 7, 2026.

This reflects typical equity compensation mechanics. Actual share sale activity is not indicated here; outcomes depend on future vesting and any subsequent transactions disclosed.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Levine Jon R

(Last) (First) (Middle)
C/O MARIMED INC.
10 OCEANA WAY

(Street)
NORWOOD, MA 02062

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 11/07/2025 M 75,000 A $0(1) 21,028,494 D
Common stock 11/07/2025 F 22,013(2) D $0.097 21,006,481 D
Common stock 6,684,640 I By the Jon Levine Family Trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (RSU) (1) 11/07/2025 M 75,000 (4) (4) Common Stock, par value $.001 per share 75,000 $0 150,000 D
Explanation of Responses:
1. RSUs convert to shares of common stock on a one-for-one basis.
2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.
3. These shares are held in trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
4. These RSUs were granted on November 7, 2023; the remaining RSUs will vest in two equal installments, on each of May 7, 2026 and November 7, 2026, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.
Remarks:
/s/ Jon R. Levine 11/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MRMD’s CEO report on Form 4?

He reported the conversion of 75,000 RSUs to common stock (Code M) and withholding of 22,013 shares for taxes (Code F).

How many MRMD shares does Jon R. Levine hold after the transactions?

He holds 21,006,481 shares directly and 6,684,640 shares indirectly via the Jon Levine Family Trust.

What prices are associated with the reported MRMD transactions?

The RSU conversion occurred at $0; shares withheld for taxes were priced at $0.097.

How many MRMD RSUs remain for Jon R. Levine and when do they vest?

He has 150,000 RSUs remaining, vesting in equal installments on May 7, 2026 and November 7, 2026.

What do transaction codes M and F mean on MRMD’s Form 4?

M indicates an RSU conversion to shares; F indicates shares withheld to cover tax obligations.

Is the indirect ownership of MRMD shares attributed to Jon R. Levine?

The filing notes 6,684,640 shares are held by a family trust; he disclaims beneficial ownership of those securities.
Marimed

OTC:MRMD

MRMD Rankings

MRMD Latest News

MRMD Latest SEC Filings

MRMD Stock Data

56.49M
280.32M
14.7%
0.24%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Norwood